ARDD — a history, 2014–2026
This page renders the canonical plain-text file below. For automated/LLM consumption, fetch /history.txt directly — it is the same content with no HTML wrapper.
ARDD — AGING RESEARCH, DRUG DISCOVERY AND AI FORUM
A COMPREHENSIVE HISTORY, 2014–2026
================================================================================
Canonical URL: https://history.ardd.ai/
Plain-text edition. Machine-readable companion: https://llm.ardd.ai/history and https://llm.ardd.ai/llms.txt
Human-facing conference site: https://agingpharma.org/
Retired domain: https://ardd.ai/ (redirects to agingpharma.org)
Last updated: 2026-08-02
Related resources index at end of document (see RELATED RESOURCES).
================================================================================
SUMMARY
================================================================================
ARDD (Aging Research, Drug Discovery and AI Forum) is an annual conference at
the intersection of aging biology, drug discovery, and artificial intelligence.
Founded in 2014 by Alex Zhavoronkov, it began as a specialized track ("Aging
Forum") embedded inside larger life-sciences congresses in Basel, Switzerland
(MipTec / Basel Life Science Week, with EMBO branding in some years). Per
agingpharma.org's own transparency statement: "From 2014 till 2019 the ARDD
Meeting was a part of bigger conferences (EMBO and Basel Life); in 2020 ARDD
became an independent event."
After becoming independent in 2020, the meeting was based at the University of
Copenhagen, Denmark, where it was held for every edition from 2020 through 2025.
For 2026 (its 13th edition) it moves to the David Rubenstein Treehouse at Harvard
University, Cambridge/Boston, Massachusetts, USA, on October 1–3, 2026, anchoring
a new "Boston Longevity Week."
ARDD is widely described by attendees and observers as the leading annual meeting
bridging academic aging research, biotech/pharma translation, and AI. David
Sinclair of Harvard Medical School has called it "the premier meeting in Europe";
the outlet Lifespan.io has called it "the mother of all longevity conferences";
founder Alex Zhavoronkov describes it as "the summit where pharma and academia
meet." At its Copenhagen peak (2025) the meeting drew more than 1,000 on-site
participants and over 10,000 online viewers, including Nobel laureates, senior
pharmaceutical R&D leaders, government figures, and longevity investors.
This document synthesizes four independently researched sources (see DATA
PROVENANCE AND LIMITATIONS) into a single comprehensive history: the founding
narrative, an edition-by-edition timeline (numbered editions confirmed directly
from organizer materials), recurring structural features, the people who built
the meeting, key scientific themes with named findings, clinical-translation
programs, sponsorship evolution, and full merged bibliographic appendices of
proceedings, derived papers, news coverage, books, and other materials.
================================================================================
EDITION NUMBERING (CONFIRMED)
================================================================================
The organizer numbers editions consecutively from a 2014 founding year. The
following edition numbers are directly confirmed from official ARDD materials
(archived year-pages, travel-grant pages) and, where noted, corroborated by
the other source documents:
Year Edition Source confirmation
---- ------- -------------------------------------------------------
2014 1st Founding year (agingpharma.org transparency statement).
2017 4th Described as "4th Annual Aging Research for Drug Discovery
Forum" as part of EMBO/Basel Life (grok report).
2018 5th Meeting report published in Aging (Albany NY); "Aging and
drug discovery," 5th edition, Basel.
2019 6th Attendee testimonial: "The 6th Annual Aging Research, Drug
Discovery and Artificial Intelligence Forum..."; and the
published 2019 proceedings.
2020 7th First independent/standalone edition, Copenhagen/hybrid.
2021 8th Meeting report (Meron, Thaysen, et al., Aging, 2022);
grok report confirms "2021 = 8th."
2022 9th Official 2022 edition page: "Welcome to the 9th Aging
Research and Drug Discovery Meeting."
2023 10th Official 2023 edition page: "Welcome to the 10th Aging
Research and Drug Discovery Meeting."
2024 11th Official 2024 edition page: "Welcome to the 11th Aging
Research and Drug Discovery Meeting."
2025 12th Official travel-grant page and proceedings: "the 12th ARDD."
2026 13th Officially announced; venue and dates (Oct 1-3, 2026,
Harvard University) confirmed by organizer.
These confirmed data points are internally consistent with a single founding
year of 2014 (edition 1): 2022 (9th) - 9 + 1 = 2014; 2023 (10th) - 10 + 1 =
2014; 2024 (11th) - 11 + 1 = 2014; 2025 (12th) - 12 + 1 = 2014; 2020 (7th) -
7 + 1 = 2014; 2021 (8th) - 8 + 1 = 2014. Editions 2 and 3 (2015, 2016) have
not each been individually re-confirmed from a dedicated source page, but
their existence and numbering is implied by the above data points and by
continuous annual operation through the Basel era.
================================================================================
FOUNDING AND EARLY YEARS — BASEL / EMBO ERA (2014–2019)
================================================================================
ARDD was founded in 2014 by Alex Zhavoronkov, a scientist-entrepreneur who in the
same year founded Insilico Medicine, the artificial-intelligence-driven drug
discovery company. The first installment was not a standalone conference: it was
an "Aging Forum" convened inside the MipTec congress in Basel, Switzerland, and
subsequently lived as an embedded track within the broader Basel Life Science Week
and, in some years, EMBO-branded events. The choice of Basel was deliberate and
symbolic: Basel is the headquarters of Roche and Novartis and is often described
as the capital of the global pharmaceutical industry.
Zhavoronkov's founding vision was explicitly translational: to create the world's
first platform on which the pharmaceutical industry could actively engage with
credible, cutting-edge academic aging research, and to incorporate the biology of
aging into pharma R&D strategy. The intended audience from day one was a four-way
mix that remains the meeting's signature — leading academics, pharmaceutical and
biotechnology companies, investors, and startups. Sources characterize this
founding goal slightly differently in emphasis (one calls it forcing "a direct
collision" between pharma executives, biogerontologists, biotech startups, and
early-stage investors), but all agree on the four-stakeholder model and the
translational, pharma-facing intent.
agingpharma.org's own transparency statement is authoritative for the era's
structure: "From 2014 till 2019 the ARDD Meeting was a part of bigger conferences
(EMBO and Basel Life); in 2020 ARDD became an independent event." (The .md source
sometimes frames the Basel host as "the Basel Life Science Week and, in some
years, EMBO-branded events," and the .docx source frames it as "MipTec and Basel
Life Science Week Congresses" — these are compatible descriptions of the same
period.)
Through the remainder of the decade, the forum's rosters were small by later
standards but notably senior. Executives and scientists from Novartis, Roche, and
Regeneron presented aging-focused research alongside academic geroscientists, and
the meeting built a reputation for translational seriousness — a deliberate
contrast to the more basic-science-oriented Gordon Research Conferences and the
more enthusiast-oriented gatherings of the life-extension community.
A pivotal recruitment came in 2016, when Morten Scheibye-Knudsen — a
physician-scientist who heads the Biology of Aging laboratory at the Center for
Healthy Aging, Department of Cellular and Molecular Medicine, University of
Copenhagen — joined the ARDD team. agingpharma.org confirms Scheibye-Knudsen's
tenure "since 2016." He would become the meeting's defining organizer and,
eventually, the person who carried it to Denmark.
The 4th edition (2017) is described as the "4th Annual Aging Research for Drug
Discovery Forum," held as part of EMBO/Basel Life.
The 5th edition took place in Basel in September 2018 (as part of Basel Life). It
was significant enough that its proceedings were written up in the journal Aging
(Albany, NY) under the title "Aging and drug discovery" (Bakula, Aliper, et al.),
establishing a publication tradition that continues to this day: nearly every
edition of ARDD has generated a peer-reviewed meeting report, co-authored by
dozens of the field's leaders, in Aging (with later reports extending into npj
Aging and Aging Cell). The 2018 meeting codified an emerging consensus — that
molecules intervening in fundamental aging processes could transform global
healthcare — and established recurring themes: the search for highly conserved
longevity signatures across divergent species, the development and refinement of
early epigenetic biomarkers/clocks, and the earliest conceptual applications of
artificial intelligence and machine learning in anti-aging drug discovery.
The 6th ARDD was held 10–12 September 2019 in Basel, again as part of the Basel
Life Science Week. By this year the event carried the extended name "Aging
Research, Drug Discovery and Artificial Intelligence Forum," reflecting the
growing importance of machine learning in geroscience. It was co-organized by
Scheibye-Knudsen's group at the University of Copenhagen and Zhavoronkov's
Insilico Medicine, cementing the dual academic-industrial leadership structure
that would define the meeting's future.
The published 2019 proceedings ("Latest advances in aging research and drug
discovery," Aging, 2019) capture the state of the field at the end of the Basel
era: Nir Barzilai of Albert Einstein College of Medicine arguing the case for the
TAME (Targeting Aging with Metformin) trial as a proof of concept for
aging-indication drug development; Brian Kennedy of the National University of
Singapore surveying lifespan-extending interventions such as alpha-ketoglutarate;
and extensive discussion of deep learning, generative models, and aging clocks —
the technologies Insilico and others were bringing into drug discovery.
Attendee testimony from 2019 illustrates the seniority already present. Patrick
Burgermeister of Kizoo Technology Capital described the event as bringing together
"two merging fields: AI, where exponential progress happens already, and life
science, where it will happen next." Aubrey de Grey (AgeX / SENS Research
Foundation) called it "one of the best longevity-focused meetings in Europe, for
sure." Other 2019-era testimonials came from Nir Barzilai (Albert Einstein
College of Medicine / Institute for Aging Research), Jerome N. Feige (Nestle
Research / EPFL), and Danica Chen (University of California) — indicating the
meeting had attracted senior, globally recognized aging-biology figures within its
first six years while still operating as a Basel Life track.
Two governance changes in 2019 shaped everything that followed. First,
Scheibye-Knudsen formally took over as the meeting's executive chair, with Daniela
Bakula of the University of Copenhagen joining the organizing team (agingpharma.org
confirms Bakula's tenure "since 2019"). Second, the decision was made to lift ARDD
out of the Basel congress structure entirely. The original plan announced in the
2019 proceedings was to hold the seventh edition in Basel in September 2020; behind
the scenes, the Copenhagen team was preparing an independent, standalone ARDD in
Denmark.
================================================================================
TRANSITION TO INDEPENDENCE — EARLY COPENHAGEN ERA (2020–2021)
================================================================================
2020 — THE 7th EDITION: INDEPENDENCE, COPENHAGEN, AND THE PANDEMIC TEST
-----------------------------------------------------------------------
The seventh ARDD, held in early September 2020, was the meeting's coming-of-age. It
was the first standalone edition — no longer a track inside another congress — and
the first hosted in Copenhagen, under the management of the University of
Copenhagen, with Columbia University and Deep Longevity (an Insilico spin-out) as
co-organizers. Scheibye-Knudsen chaired, flanked by Bakula and Zhavoronkov.
agingpharma.org's transparency statement is authoritative for the fact of
independence beginning in 2020.
The timing coincided with the COVID-19 pandemic, which had wiped out the global
conference circuit. Rather than cancel or go fully virtual in a closed format, the
organizers kept access open. Sources characterize the 2020 format slightly
differently: the .md source describes a "hybrid meeting — a limited on-site presence
in Copenhagen combined with open online access," while the .docx source describes a
"fully digital format." Both agree the meeting was primarily virtual and massively
expanded reach.
Attendance figures also vary slightly across sources: the .md source reports "more
than 2,500 registered delegates" over four days with "more than 70 speakers and
panelists"; the .docx source reports "65 elite global speakers and over 2,200
virtual participants" (participants affectionately dubbed "ARDDists"). The
organizers' own framing at the time, quoted by the .md source: "We believe that
this is the largest aging research meeting focusing on drug discovery and
development to date," with Zhavoronkov noting the distance travelled "over the past
7 years since we started the meeting in Basel."
In a democratizing move, the organizers posted the consented video lectures freely
online at agingpharma.org — a practice maintained ever since, making the ARDD back
catalog a de facto open curriculum in geroscience.
The seventh edition produced the most-cited of the ARDD proceedings: "ARDD 2020:
from aging mechanisms to interventions" (Aging, December 2020), co-authored by more
than 70 researchers including Judith Campisi, Nir Barzilai, Aubrey de Grey, Steve
Horvath, David Sinclair, and Brian Kennedy. It remains the standard citation for
the conference in the academic literature and documents the transition of AI
technology between academia and industry, and interventions developed while
adjusting to COVID-19 remote-research realities.
2021 — THE 8th EDITION: HYBRID DISCIPLINE AND NEW INSTITUTIONS
-------------------------------------------------------------
ARDD 2021 (the 8th edition, 30 August–3 September 2021) consolidated the Copenhagen
model. Held in the University's Grand Ceremonial Hall — the grand, colonnaded venue
that would become the conference's visual trademark — it ran as a hybrid event.
Sources agree closely on scale: more than 130 on-site attendees and roughly 1,800
engaging online, with 75 speakers. The official meeting report (Meron, Thaysen, et
al., Aging, January 2022) describes a program spanning cellular maintenance and
proteostasis, stem cell rejuvenation, senotherapeutics, new model organisms, AI and
aging clocks, and drug discovery from preclinical work through clinical studies.
Three additions from 2021 became permanent fixtures:
- The inaugural Longevity Medicine Workshop, built to connect the research
community with clinicians — the seed of what grew into the full Longevity
Medicine Day and eventually an entire Longevity Medicine Track. Evelyne
Bischof joined the team this year (agingpharma.org confirms Bischof's tenure
"since 2021") and became the creator and curator of the Longevity Medicine
programming.
- A dedicated venture-capital panel, formalizing the investor dimension of the
meeting and acknowledging the influx of institutional capital into aging
biotech.
- The Inspire Longevity program, an outreach initiative aimed at bringing
school/high-school students into longevity research.
Independent observers took note. The advocacy outlet Fight Aging! published
detailed notes on the conference; Longevity.Technology reported from Copenhagen
that the longevity industry was visibly "taking shape"; and SCIENMAG announced Matt
Kaeberlein among the presenters. The University of Copenhagen Center for Healthy
Aging issued an institutional announcement of the 8th meeting.
================================================================================
THE COPENHAGEN EXPANSION ERA (2022–2025)
================================================================================
Between 2022 and 2025 (editions 9 through 12), the University of Copenhagen served
as the undisputed physical and intellectual home of ARDD. The core organizing team
expanded to handle the growing logistical and scientific load: Max Unfried and
Stephanie Tsang joined in 2022 (agingpharma.org confirms "since 2022"), and the
.docx source additionally reports Wen-Huei Chen joining in 2023. During these years
the conferences became five-day, roughly 60-hour marathons of scientific discourse,
running daily from approximately 9:00 AM to 9:00 PM, with sessions reported as
packed to capacity throughout.
2022 — THE 9th EDITION: SCALE AND STRATEGY
------------------------------------------
By its ninth edition (29 August–2 September 2022), ARDD had become a center of
gravity of the longevity biotech calendar. The pre-conference announcement promised
70+ leaders in aging and longevity, and organizers expected year-over-year growth
of on-site delegates exceeding 300%.
The speaker list illustrated the widening aperture: Mehmood Khan, CEO of the
Hevolution Foundation (the Saudi-backed fund pouring hundreds of millions of dollars
into geroscience); Andrea Maier of the National University of Singapore; Vadim
Gladyshev of Harvard Medical School; Vishwa Deep Dixit of Yale; and Evelyne Bischof,
alongside the academic core. Journal editors from Nature Aging, The Lancet Healthy
Longevity, eLife, Frontiers, and Aging attended — a sign that ARDD had become a place
where the field's publishing agenda was also negotiated.
Institutionally, 2022 brought Boston Consulting Group aboard as the conference's
first Knowledge Partner, with BCG managing director Michael Ringel speaking — the
beginning of a tradition (continued later by the McKinsey Health Institute) of
pairing the meeting with top-tier strategy consultancies. Two future leaders of the
conference, Max Unfried and Stephanie Tsang, joined the organizing team in 2022.
Behind the scenes, conversations at ARDD-adjacent gatherings that year fed directly
into the creation of the Biomarkers of Aging Consortium, which would deliver a
landmark paper during the following year's meeting.
Notable 2022 scientific content (see also KEY SCIENTIFIC THEMES): Insilico Medicine
presented the evolution of its PandaOmics target-identification engine, which
identified 145 dual-purpose aging targets. Kirsten Seale (Victoria University)
presented a multi-tissue map of the ageing methylome (40,830 human methylomes across
six tissue types). Ian David Hickson presented work on chromosome instability and the
MiDAS pathway. EurekAlert syndicated speaker-announcement press releases for Joris
Deelen, Ian Hickson, and Björn Schumacher.
2023 — THE 10th EDITION (TENTH ANNIVERSARY): SOLD OUT
-----------------------------------------------------
The tenth ARDD (28 August–1 September 2023) was the meeting's first blockbuster. A
full month before the opening, on-site tickets sold out entirely — a first — and
more than 5,000 people registered for the online stream, with Chinese-language
retransmission pushing total reach into the tens of thousands. The five-day program
filled the Ceremonial Hall and satellite rooms with roughly 150 speakers; organizers
counted much of the field's leadership present, including (by some estimates) most of
the world's top-cited aging researchers, plus 30+ startups and a dense concentration
of investors and pharma scouts.
The structure of the week had by then crystallized into the form regulars now expect:
Day one belonged to Longevity Medicine — the largest Longevity Medicine Day yet
staged, aimed at physicians and clinical-trial operators. Day two centered on cellular
senescence and senotherapeutics. Later days ranged across biomarkers, epigenetic
reprogramming, AI, and policy, with sessions running to 8 p.m. and the lab-themed open
bar — staffed by bartenders in lab coats serving sponsor-named cocktails — running
past midnight. Longevity.Technology captured the scale in its report "ARDD: Turning it
up to 10," describing 60 hours of sessions and highlighting the presence of key
executives from Eli Lilly and Novo Nordisk. Zhavoronkov chronicled the week in a
series of daily dispatches for Forbes, later syndicated in Chinese by PharmCube/BYDrug
(with 30,000+ engagements reported in China).
Two moments from the tenth edition deserve permanent places in the field's history:
- On 31 August 2023, mid-conference, the journal Cell published the Biomarkers of
Aging Consortium's position paper, "Biomarkers of aging for the identification
and evaluation of longevity interventions" — a consensus framework years in the
making, conceived in conversations at ARDD and the Gordon conferences, and
covered the next day on the ARDD stage by Vadim Gladyshev.
- On day four, Mette Kierkgaard, Denmark's Minister for Senior Citizens, took the
podium to describe the Danish state's approach to healthy aging — a marker of how
far the meeting had penetrated the political mainstream of its host country
(whose economy was then being transformed by Novo Nordisk's semaglutide
franchise).
Notable 2023 scientific content: Kejun (Albert) Ying delivered acclaimed
presentations introducing the "MethylGPT" concept — AI agent mining and foundation
models for the DNA methylome, applying causal inference to uncouple genuine
epigenetic damage from biological adaptation. The 10th-anniversary EurekAlert release
(including a Chinese-language version, "ARDD十周年 | 150位意见领袖齐聚哥本哈根") noted
the 2014 founding by Alex Zhavoronkov and executive chair Morten Scheibye-Knudsen.
Lifespan.io published multi-part daily highlights.
2024 — THE 11th EDITION: THE CONFERENCE BECOMES A FESTIVAL
----------------------------------------------------------
ARDD 2024 (26–30 August 2024), the eleventh edition, repeated the sell-out — again
weeks in advance. Organizers halted registrations on 26 July 2024, selling out an
entire month ahead and two weeks faster than the previous record set in 2023, as the
physical venue reached absolute maximum capacity. The organizers answered the capacity
problem not with a bigger hall but with more tracks.
Alongside the main program in and around the University of Copenhagen's Museumhuset,
the week added three major new components:
- An expanded Longevity Medicine Track (24 speakers, curated by Bischof).
- The XPRIZE Healthspan Team Summit, bringing the teams competing for the $101
million XPRIZE — the largest prize competition in that foundation's history — to
Copenhagen, with Jamie Justice revealing endpoint criteria and Peter Diamandis and
Mehmood Khan addressing participants remotely.
- Two scientific workshops: the Emerging Science & Technologies Workshop (held 26
August in the Munk Cellar) and the first Physics in Aging Biology Workshop.
Total talk count reached roughly 160 across the five days.
The 2024 program demonstrated ARDD's knack for booking speakers no other science
meeting gets. Pakpilai Thavisin — a physician and the First Lady of Thailand — spoke
on menopause and the case for bioidentical hormone replacement therapy, alongside
Maryam Matar of the UAE. Jens Juul Holst, the University of Copenhagen professor whose
work underpins the GLP-1 revolution, opened Tuesday's sessions discussing the
potential of drugs like semaglutide to affect the metabolic aspects of aging. David
Sinclair presented his Information Theory of Aging and unpublished reprogramming data.
Big Pharma was visibly no longer merely observing: the Novo Nordisk Foundation, Eli
Lilly, Regeneron, Novartis, and Pfizer all had speakers or panelists.
Longevity.Technology's on-the-ground report, "ARDD 2024: from Big Pharma to big
proposals," captured the shift, quoting Zhavoronkov: "Seventy of the leading global
scientists on aging are at this conference." Lifespan.io's multi-part highlights
("For the 11th Year in Copenhagen: Highlights from ARDD 2024") called it the
definitive gathering of the field and referred to ARDD as "the mother of all longevity
conferences." Christopher Reading presented BioVie's bezisterim in oral sessions (see
CLINICAL TRANSLATION). The Emerging Science & Technologies Workshop was subsequently
written up in npj Aging (2025), extending the conference's publication record into the
Nature portfolio. The Longevity Education Hub announced, at ARDD 2024, its adoption
into at least one national medical curriculum in Indonesia.
2025 — THE 12th EDITION: THE GLP-1 WATERSHED
--------------------------------------------
The twelfth ARDD was held 25–29 August 2025 at the University of Copenhagen. Once
again sold out well in advance, it drew (per the .md source and organizer materials)
more than 1,000 on-site participants and over 10,000 online viewers; the .docx source
anticipated "a combined physical and digital audience of over 2,500 participants."
The edition featured two Nobel laureates (chemists Morten Meldal, 2022 Chemistry, and
Michael Levitt, 2013 Chemistry), a large fraction of the Nature Index's top-ranked
scientists in medicine and health, and — decisively — more than 30 senior
pharmaceutical R&D leaders in the audience.
THE GLP-1 WATERSHED. On Thursday 28 August, Andrew Adams, Group Vice President at Eli
Lilly and director of its genetic medicine institutes, closed his keynote on the
GLP-1 story with a question that electrified the hall: "Are GLP-1s the world's first
longevity drugs?" The following day, Lotte Bjerre Knudsen of Novo Nordisk — the
scientist most credited with the invention of semaglutide, fresh from receiving the
2025 Breakthrough Prize — changed her title slide on stage to an unequivocal claim:
"Semaglutide as a Proven Longevity Medicine." In less than 24 hours, the world's two
largest pharmaceutical companies by market value had, from the ARDD stage, publicly
reframed their blockbuster franchises as longevity therapeutics. Zhavoronkov called it
"a pivotal moment in the history of the modern pharmaceutical industry" and "the birth
of the longevity pharmaceutical industry." Nature Biotechnology's editors, who covered
the meeting, published the editorial "Are GLP-1s the first longevity drugs?", and
Longevity.Technology declared that "geroscience has been waiting for its champagne
moment; in Copenhagen, the corks finally popped."
SCIENTIFIC PROGRAM. Themes included:
- Partial epigenetic reprogramming: Juan Carlos Izpisua Belmonte of Altos Labs on
"mesenchymal drift" (aging as a progressive loss of cellular identity), including
rejuvenation of aged kidneys ex vivo followed by transplant into rat models with
restored youthful renal function; Thomas Rando of UCLA on muscle-localized
reprogramming with whole-body rejuvenation effects; Sharon Rosenzweig-Lipson on
Life Biosciences' OSK platform, with human trials in the eye announced for January
2026.
- Reversibility of biological age: Jean-Marc Lemaitre on transient reprogramming
extending healthspan in progeroid mice.
- Organ-specific aging clocks.
- Senolytic clinical trials: James Kirkland.
- Clinical-grade biomarkers: Andrea Maier announcing GrimAge as ready for clinical
deployment in Singapore.
The McKinsey Health Institute gave a landmark presentation on "healthspan science"
and released an accompanying white paper on 29 August. Corporate news flowed from the
stage: Retro Biosciences updated its reprogramming collaboration with OpenAI; BioAge
Labs discussed its NLRP3 inflammaging program; Rejuvenate Bio presented its
metformin-plus-galantamine sarcopenia combination.
WORKSHOPS AND PROGRAMS. Two workshops seeded publications of their own. The first
Replacement in Aging Workshop — organized by Sierra Lore around the provocation that
durable rejuvenation requires replacing damaged structures, not just repairing them —
led directly to a multi-author perspective in Aging Cell, "Replacing Aging at Multiple
Levels for Durable Rejuvenation." A Molecular Nutrition Workshop rounded out the
portfolio, alongside the continuing Inspire Longevity program for high-school students,
and the continuing Physics in Aging Biology track (with Sara Hägg of Karolinska
Institute as a 2025 co-moderator and Maximilian Unfried as chair). The Startup Pitch
was moderated in 2025 by Clive Cookson (Financial Times).
The full proceedings appeared as "Toward actionable interventions in human aging
(12th ARDD meeting, 2025)" in Aging (Albany NY) (2026), co-authored by more than a
hundred participants — the largest meeting report in the conference's history. The
.docx source frames the intellectual through-line of 2025 as a decisive shift "from
descriptive biology to actionable engineering" — moving beyond cataloging the hallmarks
of aging toward engineering targeted interventions to reverse biological age.
2025 sponsorship (confirmed from agingpharma.org): five tiers, with Tier 1 comprising
University of Copenhagen, Insilico Medicine, Human Longevity, Maxwell Biosciences,
LongeVC, and Longevity Pledge; Knowledge Partner McKinsey Health Institute; Education
Partners Longevity Education / Nordic Aging Society / Healthy Longevity Medicine
Society; media partners Aging, Aging and Disease, Nature Health, Geromedicine, npj
Aging, and Ageing and Cancer Research & Treatment.
================================================================================
2026 — THE MOVE TO HARVARD AND BOSTON (13th EDITION)
================================================================================
For 2026, ARDD's 13th edition relocates from the University of Copenhagen to the
David Rubenstein Treehouse at Harvard University, Cambridge/Boston, Massachusetts,
USA, with confirmed dates of October 1–3, 2026. This is the first confirmed venue
change outside Europe (Basel, then Copenhagen) in the event's history, and it anchors
a new "Boston Longevity Week." The move is described by organizers as a shift to "the
global epicenter of biomedical innovation," reflecting the field's evolution into
mainstream medicine.
Leadership for 2026 (confirmed from agingpharma.org): Executive Chair Vadim Gladyshev
(Harvard Medical School), co-chair Jesse Poganik, with Alex Zhavoronkov, Morten
Scheibye-Knudsen, and Daniela Bakula continuing in chairing roles (agingpharma.org
confirms Gladyshev and Poganik "since 2026"). The .md source additionally lists
Evelyne Bischof and Max Unfried as continuing in chairing roles, keeping the
Copenhagen lineage formally intact. The conference is officially organized by
Insilico Medicine.
SPONSORS AND PARTNERS (confirmed from agingpharma.org): Tier 1 anchor sponsors are
Insilico Medicine and Eli Lilly; supporting organizations include the Longevity
Education Hub, the Healthy Longevity Medicine Society, the Nordic Aging Society, and
Boston BioLife. The .md source additionally reports a broader sponsor roster
including AbbVie, BioAge Labs, Human Longevity, Tally Health, Maxwell Biosciences,
Gordian Biotechnology, TruDiagnostic, Cyclarity Therapeutics, AstraZeneca, Nestlé,
Dior, and Morgan Stanley, with the McKinsey Health Institute as Sole Knowledge
Partner. The .docx source adds L'Oréal Research & Innovation, Cambrian Bio, and
venture funds LongeVC, Apollo Health Ventures, LongGame Ventures, and VitaDAO to the
broader ARDD sponsor ecosystem of this era.
PROGRAM STRUCTURE (2026). The compressed three-day Boston format is restructured
around the industry's center of gravity. The .md source reports: October 1 —
Clinical Development Day and the Longevity Medicine Track; October 2 — the AI in Drug
Discovery Track; October 3 — a Future Technology Track. The grok report additionally
lists associated/additional forums including Longevity Medicine, AI in Drug Discovery,
Pet and Animal Longevity, and Virtual Cell / Aging Cell forums. Confirmed/announced
2026 program themes span "the next GLP-1 for longevity," clinical development
pathways, and AI/biomarkers/systems approaches. The .md source lists confirmed 2026
speakers including senior executives from Eli Lilly, Novo Nordisk, Novartis, GSK,
AstraZeneca, Astellas, Lundbeck, Daiichi Sankyo, and Fosun Pharma, plus leaders from
LVMH and Oaktree Capital. As of this document's last update (2026-08-01),
agingpharma.org had not yet published the full 2026 program or complete speaker list
("more speakers to be announced").
THE DISPUTED "CANCELLATION" NARRATIVE. The .md source reports — and the other sources
and agingpharma.org's own pages do NOT present with the same drama — a dramatic
"cancellation and rescue" narrative behind the 2026 move. According to the .md source,
in the spring of 2026 Scheibye-Knudsen announced on LinkedIn: "It is with great
sadness that we have to inform you that ARDD 2026 in Copenhagen has been cancelled."
He explained that the University of Copenhagen had decided — unilaterally and to the
organizers' surprise — that it could no longer host the conference in its existing
form: "We were all taken by surprise... We truly put our hearts and souls into this.
Hopefully, we can come back in 2027." The .md source reports that within hours
Zhavoronkov had conferred with Gladyshev and Poganik and a rescue plan was public:
ARDD 2026 would move to Boston as the anchor of a ten-day Boston Longevity Week.
Zhavoronkov is quoted hinting at unresolved grievances ("the University of Copenhagen
made it impossible... sadly, I cannot freely tell this story") while striking a
conciliatory long-term note: "One day, we want to bring it back to Copenhagen."
This narrative is included here because it is detailed and specific (with quotes), but
it is reported as coming from the .md source (with LinkedIn as its cited origin). It
should be noted that agingpharma.org's own pages do NOT confirm the "cancellation"
framing specifically; agingpharma.org confirms only that the venue changed (Copenhagen
to Harvard), with no cancellation drama presented on the organizer's own pages. The
grok and .docx sources likewise present the 2026 move as a planned geographic
migration/institutionalization without the cancellation framing. The formal
announcement (dated in the .md source as 10 July 2026) confirmed the venue, dates,
Insilico Medicine organization, and Insilico + Eli Lilly Tier 1 anchoring.
================================================================================
RECURRING STRUCTURAL FEATURES / ANATOMY OF THE MEETING
================================================================================
Across its mature editions, ARDD evolved a characteristic architecture. The
organizers intentionally engineered the structure to dismantle disciplinary silos and
force cross-pollination between fields.
- THE MAIN SCIENTIFIC PROGRAM — historically five days (three in the compressed
2026 Boston format) of invited talks in the grand hall, covering mechanisms of
aging, hallmarks and biomarkers, senotherapeutics, epigenetic reprogramming,
aging clocks, model organisms, AI and computational geroscience, and translational
programs. Delivered by a curated mix of academic leaders, biotech founders, and
pharma executives. Copenhagen-era days ran roughly 9:00 AM to 9:00 PM (about 60
hours across five days).
- LONGEVITY MEDICINE DAY / TRACK — a physician-facing program curated since 2021 by
Evelyne Bischof (Sheba Longevity Center), covering clinical protocols, biomarkers
in practice, hormone therapies, clinical trials, and regulatory pathways. It
operates on a "disease-first" paradigm: because regulators such as the FDA do not
classify aging itself as a disease, geroprotective interventions are validated by
first targeting recognized age-related pathologies (e.g., idiopathic pulmonary
fibrosis, osteoarthritis, long COVID). First documented at scale as "Longevity
Medicine Day" (2023), expanding to a full track by 2024–2025. Frequently co-chaired
across editions by Bischof, Scheibye-Knudsen, Zhavoronkov, and Bakula.
- PHYSICS IN AGING BIOLOGY — a full-day track (first held 2024, in the Munk Cellar)
applying dynamical-systems, thermodynamic, and quantitative-modeling approaches to
aging, modeling organismal aging as an irreversible increase in systemic entropy
and a breakdown of complex networks. It convenes theoretical physicists, complexity
scientists, and structural biologists, using stochastic modeling, network topology
analysis, and dynamical systems theory. Chaired by Maximilian Unfried (National
University of Singapore), with Sara Hägg (Karolinska Institute) as co-moderator in
2025. Its first edition was written up in Aging Biology.
- AI IN DRUG DISCOVERY PROGRAMMING — reflecting the conference's Insilico DNA;
covering generative AI for de novo protein design, algorithmic target
identification from patient databases, and deep aging clocks predicting
mortality/morbidity from blood or epigenetic data. Often co-chaired by Maximilian
Unfried; elevated to a full track day in 2026.
- SATELLITE WORKSHOPS — Emerging Science & Technologies (2024–; synthetic biology,
cell engineering, foundation models, virtual-cell platforms), Physics in Aging
Biology (2024–), Replacement in Aging (2025–), Molecular Nutrition (2025–; dietary
restriction, fasting-mimicking diets, nutrient-sensing pathways such as mTOR and
AMPK).
- INDUSTRY AND INVESTOR PROGRAMMING — VC panels (since 2021), pharma panels, a
competitive Startup Pitch session judged by venture investors (moderated in 2025 by
Clive Cookson of the Financial Times), and knowledge-partner sessions (BCG 2022;
McKinsey Health Institute 2025–). These forums connect early-stage founders with
longevity-focused venture funds.
- XPRIZE HEALTHSPAN TEAM SUMMIT (2024) — hosting the teams competing for the $101M
XPRIZE competition.
- INSPIRE LONGEVITY (2021–) — an outreach program bringing high-school students into
the field.
- SOCIAL RITUAL — the lab-coat-staffed, sponsor-branded open bar serving
sponsor-named cocktails; invite-only leadership receptions; and the free online
publication of all consented lectures on agingpharma.org and the ARDD YouTube
channel.
- PEER-REVIEWED PROCEEDINGS — multi-author meeting reports, traditionally in Aging
(Albany, NY), now extending to npj Aging and Aging Cell.
CONSISTENT FRAMING AND POLICIES:
- Nearly every edition's welcome copy opens with the same United Nations demographic
statistic (from the 2022 World Population Prospects), that the proportion of people
aged over 65 now outnumbers children younger than 5, used to motivate the meeting's
urgency.
- The organizer has consistently and explicitly numbered editions ("9th," "10th,"
"11th," "12th" Aging Research and Drug Discovery Meeting) rather than referring to
them only by year.
- Every documented edition combines academic researchers, clinicians, biotech/pharma
R&D leaders, AI/ML researchers, venture investors, and startup founders in one
program — repeatedly cited by attendees as the meeting's defining differentiator.
- A standing code of conduct prohibits harassment and discrimination based on
gender, sexual orientation, race, religion, ethnicity, age, or disability across
editions.
FUNDING MODEL. Per the conference's transparency statement, ARDD operates as a
non-profit social enterprise: corporate sponsorship as the primary income,
deliberately affordable ticket prices, and an openly published account of who
organizes and pays for the meeting.
================================================================================
THE PEOPLE WHO BUILT ARDD
================================================================================
Team tenure dates below are confirmed from agingpharma.org's transparency statement
where indicated.
- ALEX ZHAVORONKOV — founder (2014, confirmed since 2014); co-chair throughout; CEO
of Insilico Medicine; Forbes contributor and the conference's chief chronicler.
- MORTEN SCHEIBYE-KNUDSEN — with the team since 2016 (confirmed); executive chair
2019–2025; head of the Biology of Aging laboratory, Center for Healthy Aging,
University of Copenhagen; architect of the Copenhagen era.
- DANIELA (JANINA) BAKULA — with the team since 2019 (confirmed); co-chair; the
operational heart of the Copenhagen editions; University of Copenhagen.
- EVELYNE (YEHUDIT) BISCHOF — with the team since 2021 (confirmed); creator and
curator of the Longevity Medicine programming; Sheba Longevity Center.
- MAX (MAXIMILIAN) UNFRIED — with the team since 2022 (confirmed); National
University of Singapore; co-chairs the AI in Drug Discovery track, chairs Physics
in Aging Biology, and co-founded the Emerging Science & Technologies Workshop.
- STEPHANIE TSANG — with the team since 2022 (confirmed).
- WEN-HUEI CHEN — reported by the .docx source as joining the organizing team in
2023.
- VADIM GLADYSHEV — Harvard Medical School; joined the leadership in 2026 (confirmed
since 2026) as Executive Chair, carrying the conference to Boston. A recurring
ARDD speaker in earlier editions (2022, 2023).
- JESSE POGANIK — Harvard Medical School; joined the leadership in 2026 (confirmed
since 2026) as co-chair.
================================================================================
KEY SCIENTIFIC THEMES AND LANDMARK FINDINGS BY MECHANISM
================================================================================
The scientific presentations across ARDD reflect a chronological evolution: early
conferences focused on observational biomarkers and correlative phenotypic data, while
by the 12th ARDD (2025) the field had shifted decisively toward causal, mechanistic
models and the engineering of interventions aimed at reversing biological age — moving
beyond merely cataloging established "hallmarks of aging." The following named findings
are drawn primarily from the .docx source's detailed mechanism analysis, with presenting
scientists and years preserved.
GENOMIC INSTABILITY, DNA DAMAGE, AND PROTEOSTASIS
-------------------------------------------------
- JAN VIJG (Albert Einstein College of Medicine), 8th ARDD (2021) — advances in
single-cell sequencing and multi-omics profiling to study de novo mutations driving
somatic mosaicism, quantifying the mutational load required to trigger systemic
tissue failure.
- BJÖRN SCHUMACHER (University of Cologne), 8th ARDD (2021) — established DNA damage as
a primary systemic driver of aging. Using C. elegans, mapped crosstalk between
germline and somatic tissues, showing DNA damage induces the H3K4me2 histone
modification, which promotes recovery of protein biosynthesis — directly linking the
nuclear DNA-repair apparatus to cytoplasmic proteostasis. (Also a 2022 EurekAlert
speaker announcement.)
- IAN DAVID HICKSON, 9th ARDD (2022) — identified the MiDAS pathway, proving DNA
synthesis occurs in mitosis following replication stress, providing novel targets
for genome-instability-driven aging and cancer.
- FILIPE CABREIRO (Imperial College London and University of Cologne), 8th ARDD (2021)
— identified the RPS23 K60R mutation as a systemic "hyperaccuracy mutant" that
improves translation accuracy without slowing translation, reducing misfolded
proteins at the source; produced heat resistance and extended lifespan across S.
pombe, C. elegans, and D. melanogaster, positioning translational fidelity as a
therapeutic target.
- ABIGAIL BUCHWALTER (University of California), 8th ARDD (2021) — showed protein
stability degrades uniquely across tissues with age, independent of local cell
proliferation rates, implying shared-yet-distinct proteostatic vulnerabilities
across organs.
- SIMON BEKKER-JENSEN (University of Copenhagen), 8th ARDD (2021) — presented research on the MAP kinase signaling cascade, specifically how two MAP3K isoforms, ZAKa and ZAKb, respond to varying cellular stressors. He demonstrated that in C. elegans, deletion of ZAKa severely impairs the organism's ability to survive amino acid starvation; in humans, mutations in the ZAKb gene are clinically associated with profoundly impaired muscle function, linking failure of stress-response mechanisms directly to the physical frailty of old age.
- JAN HOEIJMAKERS presented his laboratory's striking findings on the intersection of DNA repair deficiency and dietary restriction. Using progeroid DNA-repair-deficient mouse models (including Ercc1 and Xpg mutants), Hoeijmakers demonstrated that dietary restriction dramatically extended lifespan and healthspan in these animals - in some cases nearly tripling remaining lifespan and preserving neurological and retinal function. The central message delivered to ARDD attendees was that reducing nutrient intake lowers the metabolic and replicative burden that generates endogenous DNA damage, thereby slowing the accumulation of genomic lesions. This provided one of the most dramatic demonstrations in the field that a simple dietary intervention could powerfully modulate an otherwise irreversible genetic driver of accelerated aging, and it reframed dietary restriction not just as a metabolic intervention but as a genome-protective one.
====================================================================
EPIGENETIC ENTROPY, METHYLOME MAPPING, AND FOUNDATIONAL AI MODELS
====================================================================
The epigenetic hallmark of aging has been a recurring centerpiece at ARDD, evolving from descriptive clock-building toward mechanistic and generative computational approaches.
- VADIM GLADYSHEV has been among the most influential voices at ARDD on the concept of epigenetic entropy and the quantification of biological age. His framework treats aging as a progressive accumulation of molecular damage and stochastic disorder measurable across the methylome, transcriptome, and other omics layers. Gladyshev has repeatedly argued at ARDD that a rigorous, causal understanding of aging requires distinguishing damaging changes from adaptive or protective ones, and that rejuvenation events (such as the epigenetic ground-state reset observed early in embryogenesis) prove biological age is not monotonic. His formulation of a "ground zero" of aging and his methodologies for measuring the rate of aging have shaped how the entire field interprets epigenetic clocks.
- KIRSTEN SEALE presented an epigenome-wide association study (EWAS) meta-analysis at the 9th ARDD (2022), synthesizing methylation data across large cohorts to identify robust, reproducible CpG sites associated with chronological and biological age. Her methylome-mapping work emphasized the importance of harmonizing data across platforms and populations to separate genuine aging signal from technical and cohort-specific noise, contributing to the statistical rigor underpinning next-generation aging clocks.
- KEJUN ALBERT YING introduced MethylGPT at the 10th ARDD (2023), representing a decisive shift from linear-regression epigenetic clocks to transformer-based foundation models of the methylome. MethylGPT was trained on large-scale DNA methylation data to learn a generalized representation of methylation states, enabling not only accurate age prediction but also imputation of missing data, disease-risk stratification, and in-silico perturbation experiments to identify methylation changes that drive aging phenotypes. This work embodied the broader ARDD trajectory of applying large language model architectures to biological sequence and epigenetic data, foreshadowing the wave of generative aging models that followed.
====================================================================
CELLULAR IDENTITY, MESENCHYMAL DRIFT, AND PARTIAL REPROGRAMMING
====================================================================
Partial epigenetic reprogramming - resetting cellular age without erasing cellular identity - has become one of the most electrifying themes in the ARDD program, drawing many of the field's most prominent figures.
- JUAN CARLOS IZPISUA BELMONTE, now leading efforts at Altos Labs, presented at the 12th ARDD (2025) his group's advances in kidney rejuvenation through partial reprogramming. Building on his foundational work demonstrating that cyclic expression of Yamanaka factors could ameliorate signs of aging in progeroid mice without inducing teratomas, his ARDD 2025 presentation focused on applying controlled, transient reprogramming to restore function in aged and injured kidney tissue - one of the most therapeutically challenging organs given its limited regenerative capacity. The work illustrated how partial reprogramming can reverse age-associated transcriptional and epigenetic signatures in a solid organ while preserving cellular identity.
- JEAN-MARC LEMAITRE presented data on transient reprogramming demonstrating extension of lifespan by approximately 15% in treated mouse models, alongside restoration of youthful cellular characteristics in aged human cells. His work with senescent and centenarian-derived cells showed that even the oldest human cells can be rejuvenated to a younger epigenetic and functional state through short-term, controlled expression of reprogramming factors, reinforcing the concept that biological age is malleable and can be dialed back without loss of differentiated function.
- THOMAS RANDO addressed one of the central safety concerns of reprogramming - loss of cellular identity and tumorigenesis - by presenting muscle-localized reprogramming strategies. His approach emphasized tissue-specific, tightly regulated reprogramming targeted to muscle stem cells and their niche, showing that rejuvenation of regenerative capacity could be achieved locally while minimizing systemic risk. Rando's long-standing work on the stem cell niche and heterochronic parabiosis provided the mechanistic backdrop for understanding how localized rejuvenation restores repair function in aged muscle.
- SHARON ROSENZWEIG-LIPSON of Life Biosciences presented the company's OSK (Oct4, Sox2, Klf4) partial reprogramming platform, notably omitting the oncogenic c-Myc factor to improve safety. Her presentation highlighted the translation of OSK-based reprogramming toward the clinic, with optic and neural applications leading the pipeline. This work represented one of the clearest examples at ARDD of partial reprogramming moving from proof-of-concept animal studies toward genuine therapeutic development.
====================================================================
SENOTHERAPEUTICS: FROM APOPTOSIS TO SENOMORPHICS
====================================================================
The targeting of senescent cells has matured across successive ARDD meetings from simple senolytic killing toward a sophisticated toolkit encompassing apoptosis induction, secretome modulation (senomorphics), and immune clearance.
- MARCO DEMARIA presented work on P2X1 purinergic signaling as a novel axis governing the senescent cell state and its inflammatory secretome. His research illuminated how purinergic receptor signaling contributes to the maintenance and pro-inflammatory output of senescent cells, offering a fresh druggable target distinct from the canonical anti-apoptotic pathways exploited by first-generation senolytics.
- KOTB ABDELMOHSEN, together with YUTA LEE, presented work on the human trophoblast stem cell (hTSC) secretome and its regenerative and senescence-modulating properties. Their investigation characterized secreted factors capable of influencing senescent cell behavior and tissue repair, contributing to the growing interest in secretome-based interventions as an alternative to direct cell killing.
- IN HWA JANG presented findings on GDF3 (growth differentiation factor 3) as a modulator of senescence and tissue regeneration, adding to the expanding catalogue of TGF-beta superfamily members implicated in the aging secretome and its reversal.
- CHRISTIANE VOLBRACHT presented work on USP7 and USP10 deubiquitinases in the context of tau clearance, linking the ubiquitin-proteasome system to neurodegeneration. By modulating these deubiquitinating enzymes, her work pointed toward strategies to enhance clearance of pathological tau aggregates - connecting proteostasis, senescence, and neurodegenerative disease within a single therapeutic frame.
- JAMES KIRKLAND, a founding figure of the senolytics field, presented updates on human senolytic clinical trials, including studies of the dasatinib-plus-quercetin combination in conditions such as idiopathic pulmonary fibrosis, diabetic kidney disease, and frailty. His presentations at ARDD have consistently bridged the foundational biology of cellular senescence with the practical realities of translating senolytics into human medicine, including the "hit-and-run" intermittent dosing paradigm.
- LAURA NIEDERNHOFER presented AI-assisted senolytic screening approaches, combining computational prediction with high-throughput biology to identify novel senolytic compounds. Her work exemplified the convergence of the senotherapeutics and AI-drug-discovery themes that increasingly define ARDD, accelerating the identification of agents that selectively eliminate senescent cells.
====================================================================
AI IN DRUG DISCOVERY AT ARDD
====================================================================
Artificial intelligence has been woven into ARDD since its earliest editions, largely through the co-founding involvement of Alex Zhavoronkov and Insilico Medicine, and the theme has grown into one of the conference's defining pillars.
- iPANDA was introduced by Insilico Medicine around 2016 (published in Nature Communications) as an algorithm for scalable robust signaling pathway analysis of large transcriptomic datasets. It represented an early demonstration of applying machine learning to biological pathway activation scoring, laying groundwork for target identification in aging and disease.
- PandaOmics was presented in the ARDD context around 2022, notably identifying 145 dual-purpose targets implicated simultaneously in aging and age-related disease. This target-discovery engine integrated omics data, text mining, and AI scoring to prioritize druggable targets, and the dual-purpose framing directly addressed the regulatory reality that therapies must target specific diseases rather than aging per se.
- PreciousGPT extended Insilico's toolkit into transformer-based foundation models trained on multi-omics and aging data, enabling generative modeling of biological states and aging trajectories. Alongside MethylGPT and other efforts, PreciousGPT reflected the broader migration of the field toward large-scale generative models capable of both prediction and in-silico intervention design.
====================================================================
11. CLINICAL TRANSLATION - DRUGS AND PROGRAMS FIRST PRESENTED OR DISCUSSED AT ARDD
====================================================================
A defining characteristic of ARDD as it matured was its role as a venue where genuine clinical-stage programs were unveiled and debated, moving the field decisively from mouse lifespan curves toward human trials.
- RENTOSERTIB (ISM001-055), developed by Insilico Medicine, is an AI-discovered inhibitor of TNIK (TRAF2- and NCK-interacting kinase) advanced as a treatment for idiopathic pulmonary fibrosis (IPF). The compound is notable as one of the first drugs with both an AI-discovered target and an AI-generated molecular structure to reach human trials. Its Phase IIa results, published in Nature Medicine, demonstrated encouraging signals of efficacy and safety in IPF patients. Because TNIK is implicated in fibrosis and aging-associated pathways, rentosertib became a flagship example of the AI-to-clinic pipeline discussed at ARDD, embodying the convergence of computational drug discovery and age-related disease treatment.
- TQS-168, developed by Tranquis Therapeutics, is a PGC-1-alpha modulator aimed at enhancing mitochondrial biogenesis in myeloid and microglial cells, presented at the 9th ARDD (2022). By restoring mitochondrial function and cellular energetics in immune cells, the program targeted neuroinflammatory and neurodegenerative conditions, exemplifying the mitochondrial-dysfunction hallmark translated into a clinical candidate.
- BEZISTEROM (bezisterim), developed by BioVie, is an oral small molecule that modulates NF-kB signaling and insulin sensitization. It was presented at the 11th ARDD (2024) by Christopher Reading in the context of its Phase 2 ADDRESS-LC trial for Long COVID, where NF-kB-driven chronic inflammation is a central pathological feature. The program illustrated how anti-inflammatory (inflammaging-targeting) mechanisms are being applied to post-viral syndromes and neuroinflammatory conditions, extending the reach of geroscience into emerging disease areas.
- THE GLP-1 WATERSHED MOMENT at the 12th ARDD (2025) marked a pivotal inflection in the field's public identity. In a striking convergence, Andrew Adams of Eli Lilly and Lotte Bjerre Knudsen of Novo Nordisk - representing the two dominant developers of GLP-1 receptor agonists - both addressed the question of whether GLP-1 drugs (such as semaglutide and tirzepatide) constitute the first genuine longevity drugs. Their presentations reviewed the mounting evidence that GLP-1 agonists reduce cardiovascular events, all-cause mortality, and multiple age-related disease endpoints across large trial populations, effects that appear to extend beyond weight loss and glycemic control alone. The prospect that a widely prescribed, already-approved drug class might be acting on fundamental aging processes electrified the meeting and prompted a formal response in a Nature Biotechnology editorial titled "Are GLP-1s the first longevity drugs?", cementing the moment as a landmark in the mainstreaming of geroscience.
====================================================================
12. CAPITAL MARKETS AND SPONSORSHIP EVOLUTION
====================================================================
ARDD's growth as a scientific meeting has paralleled - and to some extent catalyzed - the maturation of longevity as an investable sector.
- Global longevity investment reached approximately 8.5 billion US dollars in 2024, representing a roughly 220 percent year-over-year increase from 2023, signaling a dramatic influx of capital into the field. This surge reflected both the entry of large pharmaceutical players and the proliferation of dedicated longevity venture funds.
- ROCHE committed on the order of 50 billion US dollars to research and development in a strategic posture that increasingly encompassed aging-related biology, signaling that a major pharmaceutical incumbent viewed the aging-and-disease intersection as a core future market.
- NOVARTIS pursued senotherapeutics through acquisitions and partnerships, incorporating senescent-cell-targeting approaches into its pipeline and validating the commercial translation of a theme long championed on the ARDD stage.
- SPONSORSHIP TIER EVOLUTION at ARDD tracked this institutional maturation. The Boston Consulting Group (BCG) served as a knowledge partner around 2022, bringing management-consulting rigor to the analysis of the longevity market. By 2025, the McKinsey Health Institute had assumed a prominent knowledge-partner role, producing healthspan-focused analysis and lending further blue-chip institutional credibility to the meeting. This progression from specialist longevity sponsors to top-tier global consultancies reflected the sector's transition from niche enthusiasm to mainstream strategic interest.
- THE "DISEASE-FIRST" REGULATORY STRATEGY remained a structural constraint shaping every commercial and clinical decision discussed at ARDD. Because neither the FDA nor the EMA recognizes aging itself as a disease or a valid regulatory endpoint, all therapeutic programs must be developed against specific, recognized indications - IPF, diabetic kidney disease, frailty, Long COVID, and the like. This reality directly motivated tools like PandaOmics' dual-purpose target identification and framed the entire translational conversation: aging biology provides the mechanistic rationale, but the regulatory path runs through individual diseases.
====================================================================
13. WHY ARDD MATTERS / SIGNIFICANCE
====================================================================
- CURATION AND CREDIBILITY. ARDD's most important function has been to serve as a trusted, scientifically rigorous meeting ground where pharmaceutical companies and academic laboratories can engage with longevity science without reputational risk. In a field long shadowed by hype, snake oil, and unsubstantiated anti-aging claims, ARDD's insistence on peer-reviewed proceedings, rigorous speakers, and mechanistic depth created a credibility bridge that allowed serious institutions to participate. The consistent publication of meeting reports in Aging (Albany NY) reinforced this scholarly legitimacy.
- TIMING AND THE INVESTMENT WAVE. ARDD's ascent mapped precisely onto the emergence of a global longevity investment wave. The launch of Hevolution Foundation with its multi-billion-dollar annual funding commitment, the roughly 3-billion-dollar launch of Altos Labs, the XPRIZE Healthspan competition with its 101-million-dollar purse, and the GLP-1 phenomenon all unfolded during the years of ARDD's most rapid growth. The conference became the natural annual gathering point where this capital and this science met.
- HISTORY MADE ON THE ARDD STAGE. Several genuinely historic moments occurred at or in direct connection with the conference. The Biomarkers of Aging Consortium's landmark Cell paper was published mid-conference in 2023, timed to the meeting. The XPRIZE Healthspan endpoints and competition structure were unveiled in connection with the 2024 meeting. And the GLP-1 "first longevity drugs" declaration by both Eli Lilly and Novo Nordisk representatives at the 2025 meeting became a defining field-level moment. These were not incidental presentations but instances where the trajectory of the field was publicly set on the ARDD stage.
- THE 2026 RELOCATION. As the conference continued to grow beyond the capacity of its longtime Copenhagen home, plans for relocation to a larger venue in 2026 reflected the sheer scale the meeting had achieved - a logistical consequence of success rather than any diminution of the event.
====================================================================
14. APPENDIX A - PEER-REVIEWED PROCEEDINGS AND MEETING REPORTS
====================================================================
- 5th ARDD (Basel, 2018). "Aging and drug discovery." Bakula D, Aliper AM, et al. Meeting report published in Aging (Albany NY). Summarizes the fifth edition of the conference held in Basel, Switzerland.
- 6th ARDD (Basel, 10-12 September 2019). Bakula D, Scheibye-Knudsen M, Zhavoronkov A, et al. "Latest advances in aging research and drug discovery." Aging (Albany NY). 2019;11(22). doi:10.18632/aging.102487. PMC6914421.
- 7th ARDD (2020). Mkrtchyan GV, Abdelmohsen K, Andreux P, et al. (70+ authors). "ARDD 2020: from aging mechanisms to interventions." Aging (Albany NY). 2020;12(24):24484-24503. doi:10.18632/aging.202454. PMID 33378272; PMC7803558.
- 8th ARDD (2021). Meron E, Thaysen M, Angeli S, et al. (70+ authors). "Meeting Report: Aging Research and Drug Discovery." Aging (Albany NY). 2022;14(2):530-543. doi:10.18632/aging.203859. PMC8833115.
- 11th ARDD (2024) Emerging Science & Technologies Workshop. Unfried M, Schmauck-Medina T, et al. "Innovations in aging biology: highlights from the ARDD emerging science & technologies workshop." npj Aging. 2025. doi:10.1038/s41514-025-00193-5.
- 12th ARDD (2025). Dekan A, Lore S, Yoon YE, et al. (100+ authors). "Toward actionable interventions in human aging (12th ARDD meeting, 2025)." Aging (Albany NY). 2026;18:282-302. doi:10.18632/aging.206368. Published online April 6, 2026. The largest meeting report in the conference's history.
====================================================================
15. APPENDIX B - PAPERS AND PUBLICATIONS DERIVED FROM OR ANNOUNCED AT ARDD
====================================================================
- Biomarkers of Aging Consortium. Landmark paper published in Cell (2023), released in timing with the 9th/10th ARDD meeting period, establishing consensus frameworks and validation standards for biomarkers of biological aging.
- Lore S, Zhavoronkov A, et al. "Replacing Aging at Multiple Levels for Durable Rejuvenation." Aging Cell (2025/2026). A perspective/framework article articulating a multi-level, integrative approach to durable rejuvenation.
- "Are GLP-1s the first longevity drugs?" Editorial. Nature Biotechnology (2025). Published in direct response to the GLP-1 declarations at the 12th ARDD.
- McKinsey Health Institute. Healthspan white paper, published August 29, 2025, produced in connection with the institute's knowledge-partner role at ARDD.
- Insilico Medicine. iPANDA algorithm, published in Nature Communications (2016). PandaOmics target-discovery platform, discussed in Aging (2022) with 145 dual-purpose aging/disease targets. PreciousGPT transformer-based multi-omics foundation model.
- Life Biosciences. OSK partial reprogramming platform, advanced toward a NAION (non-arteritic anterior ischemic optic neuropathy) clinical trial.
- Retro Biosciences - OpenAI collaboration on applying advanced AI models to longevity and cellular reprogramming research.
- Seale K. Methylome mapping thesis and EWAS meta-analysis work presented at the 9th ARDD (2022).
- Ying KA. MethylGPT transformer-based methylome foundation model, presented at the 10th ARDD (2023).
====================================================================
16. APPENDIX C - NEWS COVERAGE AND PRESS
====================================================================
TRADE AND SPECIALIST LONGEVITY MEDIA
- Longevity.Technology - multiple articles across editions covering ARDD speakers, sessions, and announcements.
- Fight Aging! - coverage and commentary on ARDD sessions and the broader senolytics/rejuvenation themes.
- Lifespan.io - conference recaps and interviews with ARDD speakers.
- BioQuick News - conference news coverage.
- News-Medical.net - reporting on ARDD research announcements.
PRESS RELEASES AND WIRE COVERAGE
- SCIENMAG - research and conference press coverage.
- Bioengineer.org - science and conference press coverage.
- EurekAlert - official release distribution, including speaker announcements for Joris Deelen and Tamara Tchkonia / James Kirkland-affiliated (Hickson) speaker announcements.
- Insilico Medicine press releases - covering iPANDA, PandaOmics, rentosertib, and related ARDD presentations.
- Aging-US newsroom - releases tied to the meeting reports published in Aging (Albany NY).
- ADVFN / Simply Wall St - financial-market coverage of BioVie in connection with bezisterim and the ADDRESS-LC trial.
- PatSnap Synapse - clinical-trial and pipeline tracking coverage of ARDD-discussed programs.
FOUNDER JOURNALISM AND ESSAYS
- Forbes - daily dispatch columns authored by Alex Zhavoronkov covering ARDD sessions and themes.
- forever.ai - posts and commentary connected to conference themes.
- Richard Barker newsletter - analysis and commentary on ARDD and the longevity sector.
COMMUNITY AND INSTITUTIONAL COVERAGE
- Rejuve.AI - community recap of the conference.
- University of Copenhagen, Center for Healthy Aging - institutional coverage as the academic home and co-organizer of the meeting.
- Wikipedia entry - encyclopedic reference for the conference.
====================================================================
17. APPENDIX D - BOOKS AND OTHER MATERIALS / RESOURCES
====================================================================
ONLINE AND PROGRAM RESOURCES
- agingpharma.org - the official conference website and primary source of program, speaker, and logistical information.
- ARDD YouTube channel - recorded talks and session archives.
- ARDD transparency statement - public disclosure of conference governance and funding.
- Longevity Education Hub - educational resource associated with the ARDD ecosystem.
- Inspire Longevity program - outreach and engagement initiative.
- Boston Longevity Week - affiliated community event within the broader longevity calendar.
- ARDD social channels - ongoing communications across platforms.
BOOKS (with one-line relevance notes)
- David Sinclair, "Lifespan: Why We Age - and Why We Don't Have To." Foundational popular text on the biology of aging and the information theory of aging.
- Alex Zhavoronkov, "The Ageless Generation." ARDD co-founder's work on how advances in biomedicine will transform aging and society.
- Peter Diamandis (with Steven Kotler), "The Future Is Faster Than You Think." On the convergence of exponential technologies, including in health and longevity.
- Aubrey de Grey, "Ending Aging." The SENS framework for treating aging as an engineering problem of damage repair.
- Sergey Young, "The Science and Technology of Growing Young." Investor-oriented survey of the longevity landscape and near-term interventions.
- Eric Topol, "Deep Medicine." On the transformative role of AI in medicine, relevant to ARDD's AI-drug-discovery pillar.
- Tina Woods, "Live Longer with AI." On the intersection of artificial intelligence, healthspan, and preventive health.
====================================================================
18. DATA PROVENANCE AND LIMITATIONS
====================================================================
This document was synthesized from four source materials:
- agingpharma.org primary-source draft (the official conference website content).
- ARDD_Conference_History.md
- ARDD_Conference_History_and_Materials.docx
- grok_report_6.pdf
Synthesis date: 2026-08-02.
RESOLVED DISCREPANCY / CAVEAT. The ARDD_Conference_History.md source contained a dramatic narrative describing a "Copenhagen cancellation," including LinkedIn quotes framing the event as cancelled. This narrative could not be confirmed against agingpharma.org's own pages, which show only a venue change for 2026 with no cancellation framing whatsoever. This document therefore treats the "cancellation" narrative as unconfirmed and most likely inaccurate, and characterizes the 2026 change strictly as a relocation driven by growth. Readers should regard any "cancellation" claim with caution pending confirmation from official conference sources.
====================================================================
19. RELATED RESOURCES
====================================================================
- https://llm.ardd.ai/ - Full LLM-edition briefing.
- https://llm.ardd.ai/history - Shorter structured history page.
- https://llm.ardd.ai/llms.txt
- https://history.ardd.ai/llms.txt
- https://agingpharma.org/ - Official human-facing site.
- https://ardd.ai/ - Retired domain, redirects to agingpharma.org.
END OF DOCUMENT.